PREVENT Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing

Notice of Intent to Sole SourcePREVENT Cancer Preclinical Drug Development Program:Toxicology and Pharmacology TestingThis is a sole source synopsis for the Indefinite Delivery Indefinite Quantity (IDIQ) contracts within the PREVENT Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing. This announcement constitutes the only synopsis for this requirement, is issued for notification purposes only and is not a request for competitive proposals.The National Cancer Institute (NCI) plans to issue modifications to increase the ceilings on each contract in the IDIQ Toxicology pool to provide continued support in the conduct of toxicological and pharmacological evaluations of potential cancer preventive agents for Investigational New Drug applications to the Food and Drug Administration (FDA) for phase 0, 1-3 clinical studies. This work is accomplished through studies in genotoxicity testing, general toxicology in experimental animals, reproductive toxicology

studies in rodents and rabbits and other specialized studies. The modifications for this requirement are anticipated to take place on or about September 30, 2017.The five contractors currently within the Toxicology IDIQ pool are as follows:HHSN261201500021I, SRI International, 333 Ravenswood Ave., Menlo Park, CA 94025HHSN261201500022I, Southern Research Institute, 2000 9th Ave. S., Birmingham, AL 35205HHSN261201500023I, Lovelace Biomedical & Environmental Research Institute, 2425 Ridgecrest Dr. SE, Albuquerque, NM 87108HHSN261201500024I, IIT Research Institute, 10 W. 35th Street, Chicago, IL 60616HHSN261201500026I, University of Illinois at Chicago, 506 S. Wright St. 364 Henry Admin Bldg, Urbana, IL 61801These modifications will increase the ceiling value on the Base IDIQ contracts from $9 million by $10 million to $19 million. In order to ensure operation and continuity of essential research and development services during the next two cycles of the PREVENT Program, NCI needs to increase the ceiling, which will allow for the funding of complex task orders that include immunoprevention projects associated with specialized, expensive assays and procedures, among other projects. The NCI intends to issue these modifications on a non-competitive basis to each of the five contractors in the Tox IDIQ pool in accordance with 10 U.S.C 2304(c)(1), as implemented by FAR 6.302-1(a)(2), "Only one responsible source and no other supplies or services will satisfy agency requirements."This notice is not a request for competitive proposals; however, if any interested and responsible source, especially small businesses, believes it can meet the requirements, submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Interested organizations may submit their capabilities and qualifications to perform the effort in writing to the identified point of contact not later than 3:30 p.m., Eastern Standard Time, on August 29, 2017. Such capabilities/qualifications will be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination by the Government not to compete this proposed contract action based upon responses to this notice is solely within the discretion of the Government. Oral and facsimile communications shall not be accepted in response to this notice.In accordance with FAR 16.505(b)(8), the following individual has been designated as the NIH Ombudsman for these task order contracts:Dr. Sherry MillsNIH Competition Advocate for R&D Contracts6705 Rockledge Drive, Suite 305Bethesda, MD 20892Phone: 301-435-2729E-mail: sherry.mills@nih.govDISCLAIMER: THIS NOTICE IS FOR INFORMATIONAL AND PLANNING PURPOSES ONLY. THIS IS NOT A REQUEST FOR QUOTE AND IS NOT A COMMITMENT BY THE US GOVERNMENT TO PROCURE SUBJECT PRODUCTS. NO SOLICITATION SHALL RESULT FROM THIS NOTICE. NO FUNDS ARE AVAILABLE TO ACCOUNT FOR PREPARATION OF RESPONSES TO THIS NOTIFICATION. THE GOVERNMENT WILL USE THE INFORMATION RECEIVED TO DETERMINE WHETHER OTHER SOURCES ARE AVAILABLE THAT ARE CAPABLE TO SATISFY THIS REQUIREMENT.Contact Information: Nicole Belanger, Contracting Officer, Phone 3016248754, Email belangern@mail.nih.gov - Kelly Dempsey, Contracting Officer, Phone 301-624-8788, Email kelly.dempsey@nih.gov Office Address :Bldg 244, Room 112 Frederick MD 21702 Location: National Cancer Institute, Office of Acquisitions-Treatment and Support Branch Set Aside: N/A